Earnings ·
Ocugen reports $0.01 net loss per share for Q3 2026 and holds $84.6M in cash
OCGNOcugen, Inc.
Ocugen reported a net loss of $0.01 per share for the quarter ended September 30, 2026, compared to a $0.07 loss in the prior-year period. Total operating expenses rose slightly to $19.7 million from $19.4 million, driven by higher research and development costs of $12.5 million against general and administrative expenses of $7.2 million. The company ended the quarter with $84.6 million in cash, equivalents, restricted cash, and short-term investments, providing an expected runway into 2028. Ocugen is a biotechnology company developing gene therapies for blindness diseases.